CLINICAL_TRIALS
trial_result
· 2021-04-02
Clinical Trial Update: Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines [Phase 3]
Summary
Phase 3 trial update assessing safety and efficacy of NT 201 (IncobotulinumtoxinA) for glabellar frown lines is completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merz Pharmaceuticals GmbH | Conditions: Glabellar Lines | Phase 3 | Status: COMPLETED | Results posted: 2021-04-02